Evidence map›Paper›PMID 28216899›Full record

ArticlePharmacognosy magazine

Antiprotozoal Constituents from

Fernando Calzada, Jose Correa-Basurto, Elizabeth Barbosa, David Mendez-Luna, Lilian Yepez-Mulia

Open access · greenAbstract read
In one paragraph

Article in Pharmacognosy magazine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Review
  3. Advances in pharmacological and pharmaceutical sciences · 2026
    Article
  4. Review
  5. Antiprotozoal Activity AgainstMolecules (Basel, Switzerland) · 2024
    Article
  6. Kaempferol: A Review of Current Evidence of Its Antiviral Potential.International journal of molecular sciences · 2023
    Review
  7. Review
  8. Antihyperglycemic Effects ofPharmaceuticals (Basel, Switzerland) · 2023
    Article
  9. Review
  10. Article
  11. Foods (Basel, Switzerland) · 2022
    Article
  12. Review
  13. Article
  14. Article
  15. BMC complementary medicine and therapies · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Fernando CalzadaUnidad de Investigación Médica en Farmacología, UMAE Hospital de Especialidades-2 piso CORCE Centro Médico Nacional Siglo XXI, IMSS, Av. Cuauhtemoc 330, Col. Doctores, México, D. F.
Jose Correa-BasurtoSección de Graduados y Departamento de Bioquímica, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luís y DíazMirón, México, D. F.
Elizabeth BarbosaSección de Graduados, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luís y DíazMirón, México, D. F.
David Mendez-LunaSección de Graduados y Departamento de Bioquímica, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luís y DíazMirón, México, D. F.
Lilian Yepez-MuliaUnidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, UMAE Hospital de Pediatría. Centro Médico Nacional Siglo XXI, IMSS, Av. Cuauhtemoc 330, Col. Doctores, México, D. F.
Instituto Politécnico Nacional · MXCentro Medico Nacional Siglo XXI · MXHospital de Especialidades · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

objectiveThis work was undertaken to obtain information that support the traditional use of MATERIAL AND

methodsBioassay-guided fractionation of the ethanol extract of the leaves of

resultsThe

conclusionConsidering that PFOR is a target of metronidazole; kaempferol may be a lead compound for the development of novel antiprotozoal agent. Also, these findings give support to the use of SUMMARY: Bioassay-guided fractionation of the ethanol extract of the leaves of

Indexed as

AnnonaceaeAnnona cherimolaAntiprotozoal activityEntamoeba histolyticaGiardia lambliakaempferolPiruvate: ferredoxin oxidoreductase

Identifiers

PMID28216899
PMCPMC5307900
OpenAlexW2573469045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.